Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Barbanti PieroGabriella EgeoStefania ProiettiFlorindo d'OnofrioCinzia AuriliaCinzia FinocchiLaura Di ClementeMaurizio ZuccoAlberto DorettiStefano MessinaMassimo AutunnoAngelo RanieriAntonio CarnevaleBruno ColomboMassimo FilippiMiriam TasilloSteno RinalduzziPietro QuerzaniGiuliano SetteLorenzo ForinoFrancesco ZorodduMicaela RobottiAlessandro ValenzaCecilia CamardaLaura BorrelloMarco AguggiaGiovanna ViticchiCarlo TominoGiulia FiorentiniBianca OrlandoStefano BonassiPaola Torellinull null

Published in: Neurology and therapy (2024)

Keyphrases

randomized controlled trial
systematic review
double blind
open label
cross sectional
study protocol